Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 1
2010 1
2011 5
2012 2
2013 2
2014 5
2015 4
2016 4
2017 2
2018 3
2019 2
2020 4
2021 4
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Intraoperative radiotherapy (IORT) as boost in breast cancer.
Sedlmayer F, Reitsamer R, Wenz F, Sperk E, Fussl C, Kaiser J, Ziegler I, Zehentmayr F, Deutschmann H, Kopp P, Fastner G. Sedlmayer F, et al. Among authors: zehentmayr f. Radiat Oncol. 2017 Jan 19;12(1):23. doi: 10.1186/s13014-016-0749-9. Radiat Oncol. 2017. PMID: 28103903 Free PMC article. Review.
High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC.
Grambozov B, Stana M, Kaiser B, Karner J, Gerum S, Ruznic E, Zellinger B, Moosbrugger R, Studnicka M, Fastner G, Sedlmayer F, Zehentmayr F. Grambozov B, et al. Among authors: zehentmayr f. Cancers (Basel). 2022 Jan 23;14(3):573. doi: 10.3390/cancers14030573. Cancers (Basel). 2022. PMID: 35158841 Free PMC article. Review.
Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.
Grambozov B, Kalantari F, Beheshti M, Stana M, Karner J, Ruznic E, Zellinger B, Sedlmayer F, Rinnerthaler G, Zehentmayr F. Grambozov B, et al. Among authors: zehentmayr f. Radiother Oncol. 2023 Aug;185:109728. doi: 10.1016/j.radonc.2023.109728. Epub 2023 Jun 9. Radiother Oncol. 2023. PMID: 37301259 Free article.
Boost IORT in Breast Cancer: Body of Evidence.
Sedlmayer F, Reitsamer R, Fussl C, Ziegler I, Zehentmayr F, Deutschmann H, Kopp P, Fastner G. Sedlmayer F, et al. Among authors: zehentmayr f. Int J Breast Cancer. 2014;2014:472516. doi: 10.1155/2014/472516. Epub 2014 Sep 2. Int J Breast Cancer. 2014. PMID: 25258684 Free PMC article. Review.
Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3.
Zellinger B, Bodenhofer U, Engländer IA, Kronberger C, Grambozov B, Ruznic E, Stana M, Karner J, Fastner G, Sotlar K, Sedlmayer F, Zehentmayr F. Zellinger B, et al. Among authors: zehentmayr f. Breast Cancer. 2022 Mar;29(2):274-286. doi: 10.1007/s12282-021-01308-y. Epub 2021 Dec 5. Breast Cancer. 2022. PMID: 34865205 Free PMC article.
Hsa-miR-375/RASD1 Signaling May Predict Local Control in Early Breast Cancer.
Zellinger B, Bodenhofer U, Engländer IA, Kronberger C, Strasser P, Grambozov B, Fastner G, Stana M, Reitsamer R, Sotlar K, Sedlmayer F, Zehentmayr F. Zellinger B, et al. Among authors: zehentmayr f. Genes (Basel). 2020 Nov 26;11(12):1404. doi: 10.3390/genes11121404. Genes (Basel). 2020. PMID: 33255991 Free PMC article.
43 results